China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global first-in-man (FIM) clinical study of its MonarQ transcatheter tricuspid valve replacement (TTVR) system. This marks a significant milestone in the development of innovative treatments for tricuspid regurgitation.
MonarQ TTVR System Profile
The MonarQ TTVR system is an innovative product designed to treat tricuspid regurgitation. It features a unique attachment system that aligns with the biodynamics of the heart. The system utilizes and maintains the natural motion of the heart, allowing the implant to be clamped on the primary lobule to disperse the systolic load. This design widely adapts to the size of the primary valve ring and minimizes the occurrence of perivalvular leakage, offering a significant advancement in the treatment of tricuspid regurgitation.
Global Rights Acquisition
Peijia Medical obtained global rights to the MonarQ TTVR system in a deal with inQB8 Medical Technologies, LLC in June 2021. This strategic acquisition positions Peijia Medical at the forefront of innovation in transcatheter valve replacement technologies, enhancing its global footprint in the cardiovascular medical device market.-Fineline Info & Tech
